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Abstract 
 
Solanum nigrum L. or Leunca in Indonesia has been traditionally used as a herbal 
plant, which is believed to have anti-tumor properties, although the mechanism for the 
activity remains unknown. The resecarch aim to examine the cytotoxic effect of the 
ethanolic extract of Solanum nigrum on WiDr human colon cancer cells. In this study, we 
prepared an ethanol extract from herb of Solanum nigrum and investigated the mechanism 
involved in its growth-inhibitory effect on WiDr human colon cancer cells. Herbs of 
Solanum nigrum dry powder is extracted with 70% ethanol then added into the WiDr cell 
culture in 96 wells plate in various concentration : 50, 100, 250, and 500 µg/ml. 
Cytotoxicity of the Solanum nigrum ethanolic extract  was analyzed with MTT assay on 
WiDr human colon cancer cell lines. Results from the MTT assay showed WiDr cells was 
weakly suppressed in the presence of the extract. The result of the assay also showed a 
very close correlation between the Solanum nigrum extract concentration and the 
surviving cell numbers which means the extract caused cell death in a dose-dependent 
fashion in WiDr cancer cells with the IC50 of 359,23 µg/ml. Collectively, the research 
suggest further studies to explore other chemopreventive possibilites of Solanum nigrum 
ethanolic extract 
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INTRODUCTION 
 
Colorectal cancer is the fourth most 
common cancer in men and the third in women. In 
2007, there are nearly 1.2 million cases of 
colorectal cancer found worldwide.  Among those 
cases, about 630,000 patients are dead, accounting 
for 8% of all cancer deaths (ACS, 2007). The 
number of colorectal cancer also increases as the 
grow of the population (Winawer, 2007).  It is 
important to seek for chemical compounds that can 
be used as chemopreventive agents against 
colorectal cancer.   
The alternative of seeking the compund that 
can treat colorectal cancer is through screening 
medicinal herbs. One of the herb that already 
reported to have anticancer activity is Solanum 
nigrum or known as Leunca in Indonesia. Its 
ethanolic extract showed cytotoxic activity against 
MCF-7 Breast cancer cell (Ji et al., 2007).  The 
major alkaloid compound of Leunca, solanine and 
solasodine also proven to be a potential anti cancer 
agent. It is also reported that methanolic extract of 
leunca showed anti- inflammatory activity against 
carrageenan induced paw edema (Ravi, 2009).  
Based on those fact we were conducted the 
study of Solanum nigrum ethanolic extract (SEE) 
cytototoxicity effect in WiDr human colon cell. It 
expressed high concentration of COX-2 an 
inflammatory agent to induce its proliferation 
(Palozza et al., 2005). And its apoptosis activity 
went through p53 independent pathway, one of 
them is through the activation of p73 (Levrero et 
al., 2000).   
 
MATERIALS AND METHODS 
 
Ethanolic Extract of Leunca (SEE) 
Dried powder of leunca herbs were 
purchased from Balai Besar Penelitian dan 
Pengembangan Tanaman Obat dan Obat 
Tradisional (B2P2TOOT), Indonesia. 
Determination were conducted by B2P2TOOT.  
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Dried powder was then extracted by maceration 
for 5 days with 70% ethanol. Filtrate collected was 
concentrated using rotary evaporator (Heidolph, 
2000).  
 
5-Florouracil 
5-Florouracil (5FU) was obtained from 
Kalbe Farma. 
 
Cell culture 
WiDr cell line was obtained from Cancer 
Chemoprevention research center (CCRC) 
laboartoty and grown in Roswell Park Memorium 
Institute (RPMI; Gibco) with 10% fetal bovine 
serum (Gibco) and 1% penicillin-streptomycin 
(Gibco) at standard culture conditions.  
 
Cytotoxicity assay 
For SEE dose-response experiments, WiDr 
cells were seeded in 96-well plates with 5 x 
10
3
cells/well and divided into control and 
treatment group. The cells then refreshed and 
cultured for 24 hours. To assess the cell viability, 
cells were treated with various concentration (1; 
10; 50; 100; 250; and 500 µg/ml) of SEE dissolved 
in dimethyl sulfoxide (DMSO). After 24 hours of 
incubation culture medium was removed and cells 
were washed in PBS (Sigma). Then, cells were 
incubated with 100 μL culture medium and 10 μL 
MTT (Sigma) 5 mg/mL in each well for 4 hours. 
The MTT reduction reaction was stopped by 10% 
solution of Sodium Dodesil Sulfat (SDS) in HCl. 
The absorbance was measured by ELISA reader 
(Bio-Rad) at wave length of 595 nm. The average 
cytotoxicity and the IC50 of extract were count 
with linear regression method by using the curve 
of Log concentration versus percentage of cell 
viability. 
 
Combination assay 
For SEE- 5FU combination, the procedure 
was the same as extract’s cytotoxicity assay except 
the cells were treated with Serial dilution of SEE at 
5-500 μg/mL was used, while 5FU was at 1000 
nM. SEE was dissolved in as stock solutions and 
diluted as desired directly in the culture medium as 
well as 5FU.  
 
 
 
RESULTS AND DISCUSSION 
 
The treatment of SEE into WiDr cells 
resulted the decreasing number of viable cells in 
dose dependent manner as seen in Fig. 1. Linear 
regression between concentration versus viability 
in percent gave the IC50 value of 359.23 µg/ml. 
The value showed that the SEE does not posses a 
potent cytotoxic activity against WiDr. The 
morphology of the cell also examined and it is 
shown in Fig. 2. From the previous study, the IC50 
value of 5-Fluorouracil against WiDr is 1000 nM 
(Ikhtiarsyah, 2009). In order to examine the 
possibility of SEE to be used as co-chemotherapy 
agent to 5FU, a screening conducted using the 
dose of 5; 50, and 500 µg/ml SEE in order to 
compare the effect of its high, middle, and low 
concentration with 1000 nM (IC50) of 5FU. The 
treatment yielded a non dose dependent number of 
cells as seen in Fig. 3. 
Single treatment of SEE yielded a dose 
dependent manner of the decreasing of WiDr cells’ 
viability. The treatment of SEE in low dose did not 
show cytotoxic activity. The number the cells even 
increases by 15 which indicated that there was no 
significant changes happen. The viability 
percentage decreased in a dose dependent manner 
as the result of treatment in higher dose: 50, 100, 
250, and 500 µg/ml. The IC50 of SEE showed that 
the SEE does not posses a potent cytotoxic activity 
against WiDr. Although previous study using HT-
29 cell, the cell which WiDr derived from, showed 
it induced apoptosis against the cell. It maybe 
caused by the genetic differences between WiDr 
and HT-29 that leads into different mechanism of 
apoptosis they may through.  
The further step of the study was to examine 
whether SEE might act as a co-chemotherapy 
agent in combination with 5FU, the drug of choice 
in colon cancer cases. The combination treatment 
yielded a non-dose dependent responds. As seen in 
Fig. 2, there’s a fluctuation in cell viability after 
the treatment. We interpret the data and conclude 
that SEE cannot be used as co-chemotherapy agent 
in combination with 5FU. The cell itself is very 
sensitive into resistance to 5FU due to it massive 
expressions of timidilat syntethase, major 
inhibiting target of 5-FU (Sigmond et al., 2003). 
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Figure 1. WiDr viability after single treatment of SEE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. WiDr viability after combinational treatment of SEE and 5FU 
 
 
CONCLUSION 
 
SEE is not potent as cytotoxic agent against 
WiDr since it inhibits 50% of cell growth in 
concentration of 359.23 µg/ml. It also decrease the 
ability of 5FU to inhibits the cells’ growth. Further 
research on its molecular mechanism shall be 
conducted. It also proven that not all 
phytochemical agents are save to be used as co-
chemotheraphy and chemopreventive agents. 
Evident-based study plays an important role in the 
screening process.  
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